Trial Profile
Phase I Study of Irinotecan Liposome (Nal-IRI), Fluorouracil and Rucaparib in the Treatment of Select Gastrointestinal Metastatic Malignancies Followed by a Phase Ib of First and Second Line Treatment of Both Unselected and Selected (for BRCA 1/2 and PALB2 Mutations) Patients With Metastatic Adenocarcinoma of the Pancreas Then Followed by a Phase II Study of First Line Treatment of Selected Patients With Metastatic Adenocarcinoma of the Pancreas With Genomic Markers (Signature) of Homologous Recombination Deficiency (HRD)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 04 Dec 2023
Price :
$35
*
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Rucaparib (Primary)
- Indications Adenocarcinoma; Biliary cancer; Colorectal cancer; Gastric cancer; Oesophageal cancer; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 29 Nov 2023 Planned End Date changed from 24 Aug 2025 to 9 Aug 2025.
- 29 Nov 2023 Planned primary completion date changed from 24 Aug 2023 to 9 Feb 2024.
- 13 Feb 2023 Status changed from recruiting to active, no longer recruiting.